Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 2/20 | 0.51 |
| ▸ | DPP4 | P27487 | 1/20 | 0.49 |
| ▸ | CTSC | P53634 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | MASP2 | O00187 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CACNA1G | O43497 | 3/20 | 0.44 |
| ▸ | F2 | P00734 | 4/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25111799 | 0.80 | CTSC (0.59) | MC4RDPP4CTSCHTR2CHTR2B | |
| SCHEMBL18576456 | 0.80 | CTSC (0.59) | MC4RDPP4CTSCHTR2CHTR2B | |
| SCHEMBL18009459 | 0.80 | CTSC (0.49) | MC4RDPP4CTSCHTR2CHTR2B | |
| SCHEMBL1162854 | 0.79 | MC4R (0.59) | MC4RDPP4CTSCHTR2CHTR2B | |
| SCHEMBL8302927 | 0.78 | MAPT (0.43) | MC4RDPP4CTSCHTR2CHTR2B | |
| SCHEMBL8302932 | 0.78 | MAPT (0.43) | MC4RDPP4CTSCHTR2CHTR2B | |
| SCHEMBL18556183 | 0.78 | CTSC (0.59) | MC4RDPP4CTSCHTR2CHTR2B | |
| SCHEMBL7067405 | 0.78 | CTSC (0.59) | MC4RDPP4CTSCHTR2CHTR2B | |
| SCHEMBL19234012 | 0.78 | MC4R (0.57) | MC4RDPP4HTR2CHTR2BMASP2 | |
| SCHEMBL6944393 | 0.77 | CTSC (0.50) | CTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034469-A1 | Heterocyclic Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-10 | — | — | US | disclosed |
| WO-2011016576-A1 | ALANINE DERIVATIVES AS INHIBITORS OF APOPTOSIS PROTEINS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034469-A1 | Heterocyclic Compound | BIRC5, XIAP, BIRC2 | MC4R 560/4885DPP4 185/4885CTSC 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.